a-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurology. 2018;75(10):1206–1214; Manfredsson FP, Tansey MG, Golde TE. Challenges in passive immunization strategies to treat Parkinson disease. JAMA Neurology. 2018;75(10):1180–1181.
65. AFFiRiS AG. AFFiRiS announces top line results of first-in-human clinical study using AFFITOPE PD03A, confirming immunogenicity and safety profile in Parkinson’s disease patients. Cision PR Newswire. June 7, 2017. www.prnewswire.com/news-releases/affiris-announces-top-line-results-of-first-in-human-clinical-study-using-affitope-pd03a-confirming-immunogenicity-and-safety-profile-in-parkinsons-disease-patients-627025511.html. Accessed June 27, 2019; Affitope PD03A. Parkinsons’s News Today. https://parkinsonsnewstoday.com/ affitope-pd03a. Accessed March 29, 2019.
66. Kuhl MM. Vaccine for Parkinson’s reports positive results from boost study. FoxFeed Blog. September 7, 2016. www.michaeljfox.org/news/ vaccine-parkinsons-reports-positive-results-boost-study. Accessed June 27, 2019.
67. Dieleman JL, Baral R, Birger M, et al. US spending on personal health care and public health, 1996–2013. JAMA. 2016;316(24):2627–2646.
68. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. New England Journal of Medicine. 2009;361(13):1268–1278; Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Archives of Neurology. 2002;59(12):1937–1943.
69. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. New England Journal of Medicine. 2009;361(13):1268–1278; Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Experimental Neurology. 2004;187(2):455–459.
70. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Experimental Neurology. 2004;187(2):455–459.
71. 45 million Americans forego medications due to costs, new analysis shows—9 times the rate of the UK [пресс-релиз]. Prescription Justice. February 6 2017. https://prescriptionjustice.org/ press_release/45-million-americans-forego-medications-due-to-costs-new-analysis-shows-9-times-the-rate-of-the-uk. Accessed June 27, 2019.
72. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of Health Economics. 2016;47:20–33.
73. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Affairs. 2006;25(2):420–428; Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy. 2011;100(1):4-17.
74. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Affairs. 2006;25(2):420–428; Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2018;20(2):273–286; Thomas DW, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M. Clinical Development Success Rates 2006–2015. Biotechnology Innovation Organization. June 2016. www.bio.org/sites/ default/files/Clinical%20Development%20 Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20 Amplion%202016.pdf. Accessed June 28, 2019.
75. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858–871; Gaffney A, Lexchin J. Healing an ailing pharmaceutical system: prescription for reform for United States and Canada. BMJ. 2018;361:k1039.
76. Bunis D. Medicare “doughnut hole” will close in 2019. AARP. February 9, 2018. www.aarp.org/health/medicare-insurance/info-2018/part-d-donuthole-closes-fd.html. Accessed March 29, 2019.
77. Pasternack A. This pioneering $475,000 cancer drug comes with a money-back guarantee. Fast Company. August 31, 2017. www.fastcompany.com/40461214/ how-novartis-is-defending-the-record-475000-price-of-its-pioneering-gene-therapy-cancer-drug-car-t-kymriah. Accessed March 29, 2019.
78. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858–871.
79. Herper M. Solving the drug patent problem. Forbes. May 2, 2002. www. forbes.com/ 2002/05/02/0502patents.html#3199af4317bc. Accessed June 28, 2019; Fox E. How pharma companies game the system to keep drugs expensive. Harvard Business Review. April 6, 2017. https://hbr. org/2017/04/how-pharma-companies-game-the-system-to-keep-drugs-expensive. Accessed June 28, 2019.
80. Table 1, cost comparison table for drugs in early and advanced idiopathic Parkinson disease. In: Rotigotine (Neupro) (Transdermal Patch) [Internet]. Canadian Agency for Drugs and Technologies in Health; 2016; Carbidopa/Levodopa. GoodRx. www.goodrx.com/carbidopa-levodopa. Accessed March 29, 2019.
81. Atlas: Country Resources for Neurological Disorders. World Health Organization; 2004.
82. WHO Model List of Essential Medicines. World Health Organization; April 2015.
83. Branswell H. Health officials set to release a list of drugs everyone on earth should be able to access. STAT. June 5, 2017. www.statnews. com/2017/06/05/essential-medicines-list-who. Accessed March 28, 2019.
84. Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. Journal of Neurology, Neurosurgery & Psychiatry. 2004;75(12):1672.
85. Там же.; Cilia R, Laguna J, Cassani E, et al. Mucuna pruriens in Parkinson disease: a double-blind, randomized, controlled, crossover study. Neurology. 2017;89(5):432–438.
Глава 9: Берем ответственность на себя
1. The Cure Parkinson’s Trust and Parkinson’s community mourn the loss of their champion Tom Isaacs. Cure Parkinson’s Trust. June 19, 2017. www.cureparkinsons.org.uk/news/cpt-pd-community-mourns-the-loss. Accessed March 14, 2019; Tom Isaacs. The Times. July 5, 2017; Obituary.
2. Palfreman J. CPT Co founder Tom Isaacs featured in the Journal of Parkinson’s Disease. Cure Parkinson’s Trust. October 30, 2013. www. cureparkinsons.org.uk/News/cpt-co-founder-tom-isaacs-featured-in-the-journal-of-parkinsons-disease. Accessed March 27, 2019.
3. Our story. Cure Parkinson’s Trust. www.cureparkinsons.org.uk/our-story. Accessed March 27, 2019.
4. Palfreman J. CPT Co founder Tom Isaacs featured in the Journal of Parkinson’s Disease. Cure Parkinson’s Trust. October 30, 2013. www. cureparkinsons.org.uk/News/cpt-co-founder-tom-isaacs-featured-in-the-journal-of-parkinsons-disease. Accessed March 27, 2019.
5. The Cure Parkinson’s Trust and Parkinson’s community mourn the loss of their champion Tom Isaacs. Cure Parkinson’s Trust. June 19, 2017. www.cureparkinsons.org.uk/news/cpt-pd-community-mourns-the-loss. Accessed March 14, 2019; Ethics. University of Notre Dame Center for Stem Cells and Regenerative Medicine. https://stemcell.nd.edu/ ethics. Accessed March 27, 2019; No research justifies the use of human embryos, Pope Francis says. Catholic News Agency. May 18, 2017. www. catholicnewsagency.com/news/no-research-justifies-the-use-of-human-embryos-pope-francis-says-22203. Accessed March 27, 2019.
6. The Cure Parkinson’s Trust and Parkinson’s community mourn the loss of their champion Tom Isaacs. Cure Parkinson’s Trust. June 19, 2017. www.cureparkinsons.org.uk/news/cpt-pd-community-mourns-the-loss. Accessed March 14, 2019.
7. Там же.; Tom Isaacs memorial. World Parkinson Coalition. www. worldpdcoalition.org/page/ TomIsaacs. Accessed March 27, 2019.
8. Grisales C. Veterans, families demand that EPA ban toxic chemical found in tap water at US military bases. Stars and Stripes. August 1, 2018. www.stripes.com/news/veterans-families-demand-that-epa-ban-toxic-chemical-found-in-tap-water-at-us-military-bases-1.540501. Accessed February 11, 2019.
9. Там же.
10. Returning EPA to its core mission. US Environmental Protection Agency. www.epa.gov/home/returning-epa-its-core-mission. Updated July 6, 2018. Accessed March 27, 2019.
11. Falce A. Congress increases research funding, shows support for care partners. FoxFeed Blog. September 28, 2018. www.michaeljfox.org/news/ congress-increases-research-funding-shows-support-care-partners. Accessed June 28, 2019.
12. Intel co-founder Andrew S. Grove dedicates portion of his estate, up to $40 million, to Michael J. Fox Foundation [пресс-релиз]. The Michael J. Fox Foundation. January 10, 2008. www.michaeljfox.org/publication/ intel-co-founder-andrew-s-grove-dedicates-portion-his-estate-40-million-michael-j-fox. Accessed June 28, 2019.
13. Reuters. Intel pioneer and Holocaust survivor Andy Grove dies at 79. Haaretz. March 22, 2016. www.haaretz.com/jewish/intel-pioneer-and – holocaust-survivor-andy-grove-dies-at-79-1.5421022. Accessed March 27, 2019; Newton C. Legendary former Intel CEO Andy Grove is dead at 79. The Verge. March 21, 2016. www.theverge. com/2016/3/21/11280004/andy-grove-intel-ceo-dies. Accessed March 27, 2019.
14. Andrew Grove. Wikipedia. https://en.wikipedia.org/wiki/Andrew_ Grove. Updated February 10, 2019. Accessed February 11, 2019.
15. Dolan KA. Andy Grove’s last stand. Forbes. January 11, 2008. www. forbes.com/forbes/ 2008/0128/070.html#462dbe0b641e. Accessed June
28, 2019.
16. Там же.
17. Pollack A, Levy J. The New York Times: Andy Grove’s prescription for health care. FoxFeed Blog.